Critical Care Therapeutics Market Research Report 2022

According to Precision Business Insights (PBI), the global critical care therapeutics market size was valued at USD 3,492.1 billion in 2021 and is poised to grow at a significant CAGR of 3.1% during the forecast period 2022 to 2028. The global Critical Care Therapeutics market is segmented into the following types: By Drug Class (Albumin, Prothrombin complex concentrates, Antithrombin concentrates, Factor XIII concentrates, Fibrinogen concentrates), By Application (Deep vein thrombosis, Pulmonary embolism (PE), Acute coronary syndrome, Atrial fibrillation, Hemodialysis, Coronary angioplasty, Surgeries) and Geography (North America, Europe, Asia Pacific, Latin America, and MEA) and forecast to 2028. Key players' profiles in the Critical Care Therapeutics market report are Baxter International Inc., Bristol-Myers Squibb Co., CSL Ltd., Grifols SA, Kedrion Spa, LFB SA, Novartis AG, Octapharma AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd. The increasing prevalence of critical illnesses across the world, a rise in the number of road accidents, an upsurge in surgeries, and the introduction of novel critical care therapeutics are some of the major factors boosting the sales of the critical therapeutics market. Critical care therapeutics have become essential medicines used across intensive care units for treating patients. Consumption of these drugs relieves pain and helps patients to recover at faster speeds.

View the detailed report description here - https://precisionbusinessinsights.com/market-reports/critical-care-therapeutics-market/

Albumin Segment to Dominate the Critical Care Therapeutics Market
Amongst the drug class, the albumin segment held a considerable market during the estimated period. increase in the prevalence of life-threatening disorders, special liver diseases, infections, and cardiac surgeries leading to hypoalbuminemia as well as the development of new albumin products by a large number of key players are some of the key factors that fuel the growth of the albumin segment. Also, the increase in demand for albumin in R&D activities, rise in non-therapeutic application of albumin, development of plant-based albumin, and rise in production of immunoglobulins & plasma collection are some of the reasons responsible for the growth of the albumin segment.

North America Critical Care Therapeutics Market
The global Critical Care Therapeutics market, based on region, is segmented into America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. The North American market is expected to increase in the global critical care therapeutics market over the forecast period. It is projected to grow at a significant CAGR in the coming years. The North American market is developing rapidly due to the heavy presence of leading pharmaceutical giants, increasing incidence of chronic diseases and accidents, well-established healthcare industry, and easy availability of various critical care therapeutics.

Strategic New Product Launches, Mergers, Acquisitions, and Agreements are the key strategies adopted by market players.

The global Critical Care Therapeutics market further reveals that the key players are increasingly adopting strategies such as the launch of newer products, product launches, and long-term alliances to improve market revenue share and gain significant geographic presence across the region. For instance,

In June 2021: NRx Pharmaceuticals revealed positive results of its ZYESAMI™ (Aviptadil) Expanded Access Protocol (EAP). COVID-19 infected patients, who had no sign of improvement by conducting other approved therapies, were given at least one dose of the drug in the ICU. Most of them were discharged from hospitals on the 28th day, unlike those treated with only ventilation..

Request sample report at- https://precisionbusinessinsights.com/request-sample/?product_id=65333

Detailed Segmentation
The Critical Care Therapeutics market is segmented based on drug class, application and geography.

Based on the Drug Class
• Albumin
• Prothrombin complex concentrates
• Antithrombin concentrates.
• Factor XIII concentrates
• Fibrinogen concentrates

Based on the Application
• Deep vein thrombosis
• Pulmonary embolism (PE)
• Acute coronary syndrome
• Atrial fibrillation
• Haemodialysis
• Coronary angioplasty
• Surgeries

Based on geography

• North America
o USA
o Canada
• Europe
o Germany
o UK
o France
o Spain
o Italy
o Russia
o Rest of Europe
• The Asia Pacific
o China
o India
o Japan
o ASEAN
o Australia & New Zealand
o Rest of Asia-Pacific
• Latin America
o Brazil
o Mexico
o Argentina
o Rest of Latin America
• MEA
o Gulf Cooperation Council (GCC) Countries
o Israel
o South Africa
o Rest of MEA

Request methodology at: https://precisionbusinessinsights.com/request-methodology?product_id=65333

Key players in the Critical Care Therapeutics Market report are Baxter International Inc., Bristol-Myers Squibb Co., CSL Ltd., Grifols SA, Kedrion Spa, LFB SA, Novartis AG, Octapharma AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd.

Contact:
Mr. Satya
Precision Business Insights | Toll Free: +1 866 598 1553
Email: sales@precisionbusinessinsights.com
Kemp House, 152 - 160 City Road, London EC1V 2NX
Website: https://precisionbusinessinsights.com/ | D U N S® Number: 852781747

About Precision Business Insights:
We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to deliver more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.

Precision Business Insights offers a variety of cost-effective and customized research services to meet particular research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.

This release was published on openPR.